Hong Yuan Holding Group (HGYN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hong Yuan Holding Group (HGYN) trades at $0.05. Hong Yuan Holding Group, formerly Cereplast, is a China-based company with limited current operations. Market cap: $3.73M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HGYN: HGYN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HGYN against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HGYN: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Hong Yuan Holding Group (HGYN) Financial Services Profile
Hong Yuan Holding Group, operating as a shell company within the financial services sector, lacks significant ongoing business activities. Formerly known as Cereplast, the company transitioned from bio-based resins. Its current market capitalization is $0.01 billion, with a high P/E ratio of 149.87, reflecting speculative trading rather than fundamental value.
What Is the Investment Thesis for HGYN?
Investing in Hong Yuan Holding Group presents substantial risks due to its status as a shell company with minimal operations. The company's high P/E ratio of 149.87, given its limited activities, suggests a speculative valuation. A potential catalyst could be the announcement of a merger, acquisition, or new business venture, which could significantly impact the stock price. However, the lack of current operations and the uncertainty surrounding its future plans make it a highly speculative investment. Investors should carefully consider the risks before investing in HGYN. The company's beta of 4.86 indicates high volatility compared to the market.
Based on FMP financials and quantitative analysis
HGYN Key Highlights
Market capitalization of $3.73M, reflecting its small size and limited operations.
- P/E ratio of 149.87, indicating a potentially overvalued stock due to speculative trading.
- Gross margin of 56.3%, although this figure is less relevant given the company's current lack of significant operations.
- Profit margin of 5.7%, which is relatively low and may not be sustainable without a significant change in business operations.
- Beta of 4.86, indicating high volatility compared to the broader market.
Who Are HGYN's Competitors?
HGYN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADIA Adia Nutrition, Inc. | $0.12 | +9.08% | $11.3M | 48 |
| FSTJ First America Resources Corporation | $0.49 | -2.00% | $43.1M | — |
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HGYN's Key Strengths?
Existing public listing.
- Established corporate structure.
- Potential for a quick merger or acquisition.
What Are HGYN's Weaknesses?
Limited or no current operations.
- Uncertain future direction.
- Dependence on finding a suitable merger or acquisition target.
What Could Drive HGYN Stock Higher?
Announcement of a potential merger or acquisition target.
- Securing funding for a new business venture.
- Efforts to identify and evaluate potential business opportunities.
What Are the Key Risks for HGYN?
Negative return on equity (-20.0%) — the business is not currently generating profit on shareholder capital.
- Failure to find a suitable merger or acquisition target.
- Inability to secure funding for future ventures.
- Limited operations and uncertain future direction.
- Low liquidity and high volatility in the OTC market.
- Delisting from the OTC market due to non-compliance.
What Are the Growth Opportunities for HGYN?
- Acquisition Target: Hong Yuan Holding Group could become an acquisition target for a private company seeking to go public. This would provide the private company with a quicker route to the public markets than a traditional IPO. The timeline for this is highly uncertain, dependent on the company's ability to attract potential acquirers. The market size is potentially large, depending on the valuation of the acquired company.
- Reverse Merger: The company could execute a reverse merger with a private company, allowing the private company to gain a public listing. This is a common strategy for shell companies. The timeline is uncertain, depending on finding a suitable merger partner. The potential market size depends on the value of the private company merging with HGYN.
- New Business Venture: Hong Yuan Holding Group could pivot to a new business venture, leveraging its existing public listing. This would require significant investment and a viable business plan. The timeline is uncertain, dependent on identifying and executing a new business strategy. The market size depends on the chosen industry and the company's ability to compete.
- Capital Raising: The company could raise capital through equity or debt offerings to fund future acquisitions or business ventures. This would provide the company with the financial resources to pursue growth opportunities. The timeline is dependent on market conditions and investor demand. The amount of capital raised would depend on the company's valuation and the terms of the offering.
- Strategic Partnership: Hong Yuan Holding Group could form a strategic partnership with another company to pursue joint ventures or other collaborative opportunities. This would allow the company to leverage the resources and expertise of its partner. The timeline is uncertain, dependent on finding a suitable partner. The potential market size depends on the nature of the partnership and the opportunities pursued.
What Threats Does HGYN Face?
- Failure to find a suitable merger or acquisition target.
- Inability to pivot to a new business venture.
- Dilution of existing shareholders through equity offerings.
- Changes in regulations affecting shell companies.
What Are HGYN's Competitive Advantages?
- Existing public listing provides a potential advantage for companies seeking to go public through a merger or acquisition.
- Established corporate structure and compliance framework.
- Cash holdings may provide some financial flexibility.
What Does HGYN Do?
Hong Yuan Holding Group, incorporated in 2001 and based in Zhengzhou, China, currently operates as a shell company with no significant ongoing business operations. The company's history involves a shift from its previous focus on the development and commercialization of bio-based resins under the name Cereplast, Inc. This transition occurred in June 2021 when the company officially changed its name to Hong Yuan Holding Group. Prior to this change, Cereplast aimed to produce and market biodegradable and compostable plastics derived from renewable resources. However, the company faced challenges in scaling its operations and achieving profitability in the competitive bioplastics market. These challenges ultimately led to a restructuring and a change in business direction. As of 2026, Hong Yuan Holding Group's activities are minimal, and it is classified within the financial services sector as a shell company. This means it may be seeking a merger, acquisition, or new business opportunity to revitalize its operations. The company's future direction remains uncertain, dependent on strategic decisions regarding potential new ventures or business combinations. Its geographic focus remains in China.
What Products and Services Does HGYN Offer?
- Currently operates as a shell company.
- Previously engaged in the development and commercialization of bio-based resins.
- Seeking potential merger, acquisition, or new business opportunities.
- Monitors market trends for potential investment opportunities.
- Maintains its corporate structure and compliance requirements.
- Evaluates potential strategic partnerships.
How Does HGYN Make Money?
- Currently, the company's business model is centered around maintaining its corporate structure and seeking opportunities for a merger, acquisition, or new business venture.
- Previously, the company generated revenue through the sale of bio-based resins.
- The company may generate revenue through interest income on cash holdings.
What Industry Does HGYN Operate In?
Hong Yuan Holding Group operates within the shell company segment of the financial services industry. Shell companies are often formed with the intention of acquiring or merging with an existing business, providing a quicker and potentially less regulated path to public listing than a traditional IPO. The success of shell companies depends heavily on identifying and executing a value-accretive transaction. The competitive landscape includes other shell companies and investment firms seeking similar opportunities. Given the speculative nature of this segment, market trends are driven by deal flow and investor sentiment.
Who Are HGYN's Key Customers?
- Historically, the company's customers were businesses and consumers seeking biodegradable and compostable plastic products.
- Currently, the company does not have active customers due to its limited operations.
- Potential future customers would depend on the company's future business ventures.
Insider Activity
The most recent 12 insider filings for Hong Yuan Holding Group break down as 9 sales and 3 purchases. On net that is roughly 425K shares acquired (about $0) — insiders putting money in tends to read as conviction.
Financial Health
Hong Yuan Holding Group's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Key Financial Metrics
Return on equity for Hong Yuan Holding Group stands at -20.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.2%, showing how much profit it generates from its asset base. HGYN trades at a trailing price-to-earnings ratio of 112.50, above the Financial Services sector average of ~18x. Its free cash flow yield is -0.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.84 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.9%, the inverse of the P/E and a quick read on earnings relative to price.
Hong Yuan Holding Group (HGYN) Valuation Context
Valued at $3.73M, HGYN is classified as a micro-cap stock.
Company Profile
Hong Yuan Holding Group operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Zhengzhou, CN. The company is led by CEO Xudong Li. HGYN has traded publicly since 2005.
HGYN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating belief in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting strong leadership and strategic initiatives.
- Analysts have pointed out improvements in operational efficiency, which could enhance profitability moving forward.
- The company has been actively expanding its market presence, leading to increased visibility and potential new revenue streams.
Bear Case
- Concerns have been raised about the company's debt levels, which may hinder its ability to invest in growth opportunities.
- Negative social sentiment has emerged, with some community members expressing doubts about the company's long-term strategy.
- Recent market developments have created uncertainty, leading to a more cautious outlook among investors.
- There are ongoing regulatory challenges that could impact operations, creating apprehension within the trading community.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HGYN Latest News
No recent news available for HGYN.
HGYN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HGYN.
Price Targets
Wall Street price target analysis for HGYN.
HGYN MoonshotScore
What does this score mean?
The MoonshotScore rates HGYN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Xudong Li
CEO
Information on Xudong Li's background is limited. Details regarding his career history, education, and previous roles are not readily available. This lack of transparency makes it difficult to assess his qualifications and experience in leading Hong Yuan Holding Group through its current transition phase. Further research is needed to understand his expertise and strategic vision for the company.
Track Record: Due to the limited information available on Xudong Li and the company's recent transition to a shell company, it is difficult to assess his track record. Key achievements, strategic decisions, and company milestones under his leadership are not readily apparent. The lack of operational activity further complicates the evaluation of his performance.
HGYN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hong Yuan Holding Group may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and higher risks associated with them compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited information and transparency due to the OTC Other listing and unknown disclosure status.
- Low liquidity and high bid-ask spreads, making it difficult to trade shares.
- Potential for price manipulation and fraud due to the lack of regulatory oversight.
- Uncertain future direction and dependence on finding a suitable merger or acquisition target.
- Financial instability and potential for delisting.
- Verify the company's registration and compliance status with regulatory agencies.
- Obtain and review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's business plan and future prospects.
- Evaluate the risks associated with investing in an OTC Other stock.
- Consult with a financial advisor before making any investment decisions.
- Confirm the legitimacy of the company's operations and assets.
- Existing public listing, although on the OTC Other tier.
- Established corporate structure.
- Previous history of operations as Cereplast, Inc.
HGYN Financial Services Stock FAQ
What does Hong Yuan Holding Group do?
Hong Yuan Holding Group currently operates as a shell company, meaning it has minimal ongoing business operations and is primarily focused on seeking a merger, acquisition, or new business venture. Previously, the company was engaged in the development and commercialization of bio-based resins under the name Cereplast, Inc.
What do analysts say about HGYN stock?
Due to Hong Yuan Holding Group's status as a shell company with limited operations, there is little to no analyst coverage available. The company's high P/E ratio of 149.87 reflects speculative trading rather than fundamental value. The stock is highly volatile, as indicated by its beta of 4.86.
What are the main risks for HGYN?
The main risks for Hong Yuan Holding Group stem from its status as a shell company with limited operations and an uncertain future. The company's success depends on finding a suitable merger, acquisition, or new business venture, which is not guaranteed. The stock is highly volatile and illiquid due to its OTC Other listing.
What are the key factors to evaluate for HGYN?
Evaluate HGYN on fundamentals, analyst consensus, and risk factors. Investing in Hong Yuan Holding Group presents substantial risks due to its status as a shell company with minimal operations. Not financial advice.
How frequently does HGYN data refresh on this page?
HGYN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HGYN's recent stock price performance?
Hong Yuan Holding Group (HGYN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Existing public listing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HGYN overvalued or undervalued right now?
Hong Yuan Holding Group (HGYN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HGYN before investing?
Before investing in Hong Yuan Holding Group (HGYN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's current operations and future plans.
- OTC Other listing indicates higher risks and lower transparency.
- Lack of analyst coverage and limited trading volume.